Skip to content

Operating margin at other companies

Alkermes logo
AlkermesALKS
12.3%-13.6pp
JAN
Janus Living JAN
-99.7%-717pp

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.53B+213%
Enterprise value$4.86B+242%
P/E18×
P/S3.5×+2.3×

Profitability

See full
Gross margin81.3%+1.5pp
Net margin19.4%+18.9pp
FCF margin-14.9%

Returns & leverage

See full
Return on equity-117%
Debt / equity-3.5×
Current ratio0.9×0.0×

Where this comes from

Calculated from Indivior Pharmaceuticals, Inc. ’s reported figures.

Based on trailing twelve months.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's operating margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's operating margin?
Indivior Pharmaceuticals, Inc. (INDV) reported operating margin of 25.8% in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's operating margin changed year-over-year?
Indivior Pharmaceuticals, Inc. 's operating margin increased by 941.6% year-over-year, from 2.5% to 25.8%.
What is the long-term trend for Indivior Pharmaceuticals, Inc. 's operating margin?
Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc. 's operating margin has grown at a 35.2% compound annual growth rate (CAGR), from -8.5% to 21.1%.
What does operating margin mean?
Operating income as a percentage of revenue (trailing twelve months). Captures profitability from core operations after both cost of revenue and operating expenses, but before interest and taxes.